|
- Somatostatin receptor 2 targeting in small cell lung carcinoma . . .
Accounting for the diversity in receptors with 5 potential receptors and the diverse signaling environment, predicting cellular responses in high grade tumors to SSTR2 agonism or antagonism is challenging
- Somatostatin Receptors - Ronny Allan - Living with Neuroendocrine Cancer
They can successfully in most cases bind with these receptors to inhibit the hormones and peptides causing the problems, particularly SSTR2 with modest affinity to SSTR5
- Somatostatin receptor2 (SSTR2) expression, prognostic implications . . .
This study aims to provide a comprehensive overview of SSTR2 expression patterns, prognostic implications, distinctive signaling pathways, epigenetic modifications, and potential therapeutic strategies associated with SSTR2 in HNSCC
- Somatostatin receptor 2 targeting peptide modifications for peptide . . .
It is reported that binding of somatostatin and analogue agonists to SSTR2 will rapidly trigger the arrestin pathway and consequent GPCR internalization into cells [28, 29], which may provide a
- Structures of the endogenous peptide- and selective non-peptide agonist . . .
In conclusion, we report two cryo-EM structures of the SSTR2–G i1 complexes bound to the peptide and selective non-peptide agonists, which provides molecular details of agonist binding and receptor subtype-selectivity (Fig 1)
- Side-by-Side Comparison of the In Vivo Performance of
These peptides, which can be either analogs or antagonists, are used in nuclear medicine for diagnostic imaging or targeted radionuclide therapy of neuroendocrine tumors that are positive for somatostatin receptors (SSTRs)
- Structures of the endogenous peptide- and selective non-peptide agonist . . .
Here, we present two cryo-electron microscopy (cryo-EM) structures of SSTR2–G i1 complexes activated by the endogenous peptide (SS-14) and a selective non-peptide agonist (L-054,264)
- Somatostatin Receptor 2 signaling promotes growth and tumor survival in . . .
SSTR2 was previously considered an inhibitory receptor on cell growth, but its agonists had poor clinical responses in multiple clinical trials The role of this receptor as a potential therapeutic target in lung cancer merits further investigation
|
|
|